Research progresses of primary liver cancer from 2017 annual meeting of Chinese Society of Clinical Oncology

Abstract

In the twentieth session of the National Clinical Oncology Conference and 2017 annual meeting of Chinese Society of Clinical Oncology (CSCO), many progre-ssions have been made in the diagnosis and treatment of primary liver cancer. (1) A preliminary report of the real world study of primary liver cancer in China was released. (2) Emerging diagnostic techniques and predictive models can detect preoperative liver cirrhosis and risk of postoperative liver failure in patients with hepatocellular carcinoma (HCC). (3) Photodynamic diagnostic technology can ensure histological clearance with nega-tive surgical margin and preserve as much liver parenchyma as possible. (4) Lenvatinib is expected to be the first-line targeted drug for the treatment of patients with unresectable HCC following sorafenib. (5) Immunotherapy with Nivolumab and Pembro-lizumab is still a hot topic in the field of HCC management. (6) Though a vast heterogeneity of patterns of liver resection for HCC exists between two large centers from the East and the West, their surgical safety and long-term efficacy are actually comparable. (7) Routine lymphadenectomy, active surgical intervention for patients with late-stage tumors, ensuring the negative margins of resection and comprehensive treatment of postoperative recurrence are expected to improve the long-term outcomes of intrahepatic cholangiocarcinoma (ICC). Key words: Liver neoplasms, primary; Sorafenib; Lenvatinib; Targeted therapy; Immunotherapy